Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
Study Details
Study Description
Brief Summary
Clinical trials, with a particular focus on recurrent ovarian cancer, play a crucial role in assessing the safety and efficacy of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to support their widespread adoption.
By actively participating in recurrent ovarian cancer observational study serves pivotal role in expanding the boundaries of medical knowledge and advancing the quality of care provided to those enduring the same condition.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Number of patients who decide to participate in a recurrent ovarian cancer clinical trial [3 months]
- Rate of patients who remain in recurrent ovarian cancer clinical research to trial completion [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged ≥ 18 years old
-
Able to comprehend the investigational nature of the protocol and provide informed consent
-
Diagnosis of recurrent ovarian cancer
Exclusion Criteria:
-
No diagnosis of recurrent ovarian cancer confirmed
-
Inability to perform regular electronic reporting
-
Patient does not understand, sign, and return consent form
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Power Life Sciences | San Francisco | California | United States | 94107 |
Sponsors and Collaborators
- Power Life Sciences Inc.
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Study Documents (Full-Text)
More Information
Publications
- Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann Oncol. 2019 May 1;30(5):721-732. doi: 10.1093/annonc/mdz104.
- Hilal Z, Schultheis B, Hartmann F, Dogan A, Cetin C, Krentel H, Schiermeier S, Tempfer CB. What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature. Anticancer Res. 2016 Oct;36(10):5365-5371. doi: 10.21873/anticanres.11110.
- Ozga M, Aghajanian C, Myers-Virtue S, McDonnell G, Jhanwar S, Hichenberg S, Sulimanoff I. A systematic review of ovarian cancer and fear of recurrence. Palliat Support Care. 2015 Dec;13(6):1771-80. doi: 10.1017/S1478951515000127. Epub 2015 Mar 2.
- 72827906